2019
Yiqi Chutan Tang Reduces Gefitinib‐Induced Drug Resistance in Non‐Small‐Cell Lung Cancer by Targeting Apoptosis and Autophagy
Zhang J, Sun L, Cui J, Wang J, Liu X, Aung T, Qu Z, Chen Z, Adelson D, Lin L. Yiqi Chutan Tang Reduces Gefitinib‐Induced Drug Resistance in Non‐Small‐Cell Lung Cancer by Targeting Apoptosis and Autophagy. Cytometry Part A 2019, 97: 70-77. PMID: 31411813, PMCID: PMC7004076, DOI: 10.1002/cyto.a.23869.Peer-Reviewed Original ResearchConceptsEpidermal growth factor receptor tyrosine kinase inhibitorsEGFR mutationsGrowth factor receptor tyrosine kinase inhibitorsDrug resistanceReceptor tyrosine kinase inhibitorsEGFR TKI-resistant cellsEGFR-TKI resistanceNew treatment strategiesGefitinib-induced apoptosisAnti-cancer effectsLower survival rateWestern blot analysisMonths treatmentMost patientsNSCLC patientsCell cycle arrestTreatment strategiesHigh incidenceMortality rateSurvival rateCancer leadFlow cytometryPatientsResistant cellsKinase inhibitors
2017
Understanding the Effectiveness of Natural Compound Mixtures in Cancer through Their Molecular Mode of Action
Aung TN, Qu Z, Kortschak RD, Adelson DL. Understanding the Effectiveness of Natural Compound Mixtures in Cancer through Their Molecular Mode of Action. International Journal Of Molecular Sciences 2017, 18: 656. PMID: 28304343, PMCID: PMC5372668, DOI: 10.3390/ijms18030656.Peer-Reviewed Original ResearchConceptsAnti-cancer agentsNatural compound mixturesTherapeutic benefitCancer progressionCancer cellsSynergistic therapeutic benefitsPotential molecular targetsPositive therapeutic benefitsAberrant apoptotic pathwaysClinical efficacyTreatment of cancerAdverse reactionsCancer managementMerit further investigationMultiple specific targetsDrug resistanceCancerGenetic abnormalitiesEffective dosageLimited evidenceMolecular targetsScientific evidenceApoptotic mechanismsFurther investigationProgression